Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski JP, Horsmans Y, Mo H, Arterburn S, Knox S, Oldach D, McHutchison JG, Manns MP, Foster GR. Zeuzem S, et al. Among authors: klinker h. Hepatology. 2012 Mar;55(3):749-58. doi: 10.1002/hep.24744. Hepatology. 2012. PMID: 22006408 Clinical Trial.
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.
Manns M, Zeuzem S, Sood A, Lurie Y, Cornberg M, Klinker H, Buggisch P, Rössle M, Hinrichsen H, Merican I, Ilan Y, Mauss S, Abu-Mouch S, Horban A, Müller TH, Welsch C, Chen R, Faruqi R, Pedicone LD, Wedemeyer H. Manns M, et al. Among authors: klinker h. J Hepatol. 2011 Sep;55(3):554-563. doi: 10.1016/j.jhep.2010.12.024. Epub 2011 Jan 13. J Hepatol. 2011. PMID: 21237227 Clinical Trial.
Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.
Sarrazin C, Schwendy S, Möller B, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Prinzing R, Herrmann E, Zeuzem S, Berg T. Sarrazin C, et al. Among authors: klinker h. Gastroenterology. 2011 Nov;141(5):1656-64. doi: 10.1053/j.gastro.2011.07.019. Epub 2011 Jul 22. Gastroenterology. 2011. PMID: 21784046 Clinical Trial.
Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients.
Grammatikos G, Lange C, Susser S, Schwendy S, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Penna-Martinez M, Badenhoop K, Zeuzem S, Berg T, Sarrazin C. Grammatikos G, et al. Among authors: klinker h. PLoS One. 2014 Feb 7;9(2):e87974. doi: 10.1371/journal.pone.0087974. eCollection 2014. PLoS One. 2014. PMID: 24516573 Free PMC article.
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
Dietz J, Müllhaupt B, Buggisch P, Graf C, Peiffer KH, Matschenz K, Schattenberg JM, Antoni C, Mauss S, Niederau C, Discher T, Trauth J, Dultz G, Schulze Zur Wiesch J, Piecha F, Klinker H, Müller T, Berg T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C; German HCV Resistance Study Group; University Hospitals; Academic Hospitals; Local study sites (private practices), Germany. Dietz J, et al. Among authors: klinker h. J Hepatol. 2023 Jan;78(1):57-66. doi: 10.1016/j.jhep.2022.08.016. Epub 2022 Aug 27. J Hepatol. 2023. PMID: 36031158
Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry.
Tacke F, Klinker H, Boeker KHW, Merle U, Link R, Buggisch P, Hüppe D, Cornberg M, Sarrazin C, Wedemeyer H, Berg T, Mauss S; DHC-R. Tacke F, et al. Among authors: klinker h. Hepatol Commun. 2022 Sep;6(9):2488-2495. doi: 10.1002/hep4.2015. Epub 2022 Jun 5. Hepatol Commun. 2022. PMID: 35666055 Free PMC article.
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.
Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S. Berg T, et al. Among authors: klinker h. Gastroenterology. 2006 Apr;130(4):1086-97. doi: 10.1053/j.gastro.2006.02.015. Gastroenterology. 2006. PMID: 16618403 Clinical Trial.
Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA.
Heidrich B, Wiegand SB, Buggisch P, Hinrichsen H, Link R, Möller B, Böker KH, Teuber G, Klinker H, Zehnter E, Naumann U, Busch HW, Maasoumy B, Baum U, Hardtke S, Manns MP, Wedemeyer H, Petersen J, Cornberg M; HepNet Study Group. Heidrich B, et al. Among authors: klinker h. PLoS One. 2014 Oct 10;9(10):e108751. doi: 10.1371/journal.pone.0108751. eCollection 2014. PLoS One. 2014. PMID: 25302676 Free PMC article.
220 results